CMV-, EBV- and ADV-specific T cell immunity: Screening and monitoring of potential third-party donors to improve post-transplantation outcome

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1480-1492

  Sukdolak, Cinja ^a   Tischer, Sabine ^a   Dieks, Daria ^a   Figueiredo, Constanca ^a   Goudeva, Lilia ^a   Heuft, Hans Gert ^a   Verboom, Murielle ^a   Immenschuh, Stephan ^a   Heim, Albert ^a   Borchers, Sylvia ^a   Mischak Weissinger, Eva ^a   Blasczyk, Rainer ^a   Maecker Kolhoff, Britta ^a   Eiz Vesper, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenovirus; Adoptive immunotherapy; Antiviral T lymphocytes; Cytomegalovirus; Epstein Barr virus; T cell therapy

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; IMMEDIATE EARLY PROTEIN BZLF1; PEPTIDE;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; DONOR SELECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FALSE POSITIVE RESULT; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH THROUGHPUT SCREENING; HLA TYPING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PERIPHERAL BLOOD MONONUCLEAR CELL; SEROLOGY; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; VIRUS; WESTERN BLOTTING;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL T LYMPHOCYTES; CYTOMEGALOVIRUS; EPSTEIN-BARR VIRUS; T CELL THERAPY;

ADENOVIRIDAE; ADULT; AGED; CYTOMEGALOVIRUS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884179048     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.015     Document Type: Article

References (56)

1. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
2. Fowler C.J., Dunlap J., Troyer D., et al. Life-threatening adenovirus infections in the setting of the immunocompromised allogeneic stem cell transplant patients. Adv Hematol 2010, 2010:601548. 10.1155/2010/601548.
3. Hebart H., Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004, 65:432-436.
4. Lucas K.G., Burton R.L., Zimmerman S.E., et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998, 91:3654-3661.
5. Brestrich G., Zwinger S., Roemhild A., et al. Generation of HCMV-specific T cell lines from seropositive solid-organ-transplant recipients for adoptive T cell therapy. JImmunother 2009, 32:932-940.
6. Einsele H., Kapp M., Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40:71-75.
7. Feuchtinger T., Opherk K., Bethge W.A., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
8. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
9. Mackinnon S., Thomson K., Verfuerth S., et al. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008, 40:63-67.
10. Haque T., McAulay K.A., Kelly D., Crawford D.H. Allogeneic T cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation 2010, 90:93-94.
11. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
12. Icheva V., Kayser S., Wolff D., et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. JClin Oncol 2012, 31:39-48.
13. Moosmann A., Bigalke I., Tischer J., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
14. Feuchtinger T., Richard C., Joachim S., et al. Clinical grade generation of hexon-specific T cells for adoptive T cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. JImmunother 2008, 31:199-206.
15. Hoffman J.A. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant 2009, 14:625-633.
16. Zandvliet M.L., Falkenburg J.H., van Liempt E., et al. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica 2010, 95:1943-1951.
17. Fujita Y., Leen A.M., Sun J., et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. JImmunother 2008, 31:665-674.
18. Khanna N., Stuehler C., Conrad B., et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011, 118:1121-1131.
19. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
20. Zandvliet M.L., van Liempt E., Jedema I., et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. JImmunother 2011, 34:307-319.
21. Casalegno-Garduno R., Schmitt A., Yao J., et al. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer Immunol Immunother 2010, 59:195-202.
22. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. JExp Med 2005, 202:379-386.
23. Schmitt A., Tonn T., Busch D.H., et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011, 51:591-599.
24. Yao J., Bechter C., Wiesneth M., et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 2008, 46:e96-105.
25. Rauser G., Einsele H., Sinzger C., et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004, 103:3565-3572.
26. Knabel M., Franz T.J., Schiemann M., et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002, 8:631-637.
27. Tischer S., Kaireit T., Figueiredo C., et al. Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8+ T lymphocytes. Int Immunol 2012, 24:561-572.
28. Kleihauer A., Grigoleit U., Hebart H., et al. Exvivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol 2001, 113:231-239.
29. Peggs K.S., Mackinnon S. Clinical trials with CMV-specific T cells. Cytotherapy 2002, 4:21-28.
30. Sili U., Huls M.H., Davis A.R., et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. JImmunother 2003, 26:241-256.
31. Cox J.H., Ferrari G., Janetzki S. Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 2006, 38:274-282.
32. Hadrup S.R., Schumacher T.N. MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother 2010, 59:1425-1433.
33. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. JVirol 1996, 70:7569-7579.
34. Ameres S., Mautner J., Schlott F., et al. Presentation of an Immunodominant Immediate-Early CD8+ T Cell Epitope Resists Human Cytomegalovirus Immunoevasion. PLoS Pathog 2013, 9:e1003383. 10.1371/journal.ppat.1003383.
35. Sylwester A.W., Mitchell B.L., Edgar J.B., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. JExp Med 2005, 202:673-685.
36. Houssaint E., Saulquin X., Scotet E., Bonneville M. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed Pharmacother 2001, 55:373-380.
37. Leen A.M., Christin A., Khalil M., et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. JVirol 2008, 82:546-554.
38. Lacey S.F., Villacres M.C., La Rosa C., et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003, 64:440-452.
39. Borchers S., Bremm M., Lehrnbecher T., et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 2013, 7:e50248.
40. Lewin S.R., Heller G., Zhang L., et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002, 100:2235-2242.
41. Loeth N., Assing K., Madsen H.O., et al. Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors. PLoS One 2012, 7:e31420.
42. Sester M., Gartner B.C., Sester U., et al. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003, 76:1229-1230.
43. Doubrovina E., Oflaz-Sozmen B., Prockop S.E., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656.
44. Elkington R., Walker S., Crough T., et al. Exvivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. JVirol 2003, 77:5226-5240.
45. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134:64-76.
46. Leen A.M., Sili U., Vanin E.F., et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 2004, 104:2432-2440.
47. Tang J., Olive M., Pulmanausahakul R., et al. Human CD8+ cytotoxic T cellresponses to adenovirus capsid proteins. Virology 2006, 350:312-322.
48. Geyeregger R., Freimuller C., Stevanovic S., et al. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One 2013, 8:e59592. 10.1371/journal.pone.0059592.
49. Franzke A., Piao W., Lauber J., et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003, 102:734-739.
50. Toh H.C., Sun L., Soe Y., et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells invivo. Clin Immunol 2009, 132:83-92.
51. Borchers S., Luther S., Lips U., et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2011, 13:222-236.
52. Amir A.L., D'Orsogna L.J., Roelen D.L., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
53. D'Orsogna L.J., Roelen D.L., Doxiadis, Claas F.H. Alloreactivity from human viral specific memory T-cells. Transpl Immunol 2010, 23:149-155.
54. Leen A.M., Christin A., Myers G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009, 114:4283-4292.
55. Melenhorst J.J., Leen A.M., Bollard C.M., et al. Allogeneic virus-specific Tcells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
56. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.